Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Business Wire 6 hours ago

INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment

Accesswire 15 hours ago

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Business Wire 1 day ago

ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Accesswire 1 day ago

INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment

Accesswire 5 days ago

Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Accesswire 7 days ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Business Wire 8 days ago

Incyte to Present at Upcoming Investor Conference

Business Wire 12 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 7, 2024

Incyte to Present at Upcoming Investor Conferences

Business Wire October 30, 2024

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire October 29, 2024

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

Business Wire October 24, 2024

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

GlobeNewswire October 15, 2024

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

Business Wire October 10, 2024

Incyte to Report Third Quarter Financial Results

Business Wire October 8, 2024

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 7, 2024

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 3, 2024

Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

Business Wire September 25, 2024

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo(TM) (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

PR Newswire September 18, 2024

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Business Wire September 14, 2024